Inflammatory bowel disease after liver transplantation: The effect of different immunosuppressive regimens

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 1, 2003, Pages 33-44

  Haagsma, E B ^a   Van Den Berg, A P ^a   Kleibeuker, J H ^a   Slooff, M J H ^a   Dijkstra, G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN A; ENEMA; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ENTERITIS; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PREDICTION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS;

EID: 0042845956     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01613.x     Document Type: Article

References (20)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
2. Chapman RWG, Arborgh BAM, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-7.
3. Wiesner RH, La Russo NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200-6.
4. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983; 85: 713-7.
5. Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-44.
6. Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 393-6.
7. Shaked A, Colonna JO, Goldstein L, Busuttil RW. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992; 215: 598-603.
8. Chalasani N, Smallwood G. Idiopathic ulcerative colitis in patients with primary sclerosing colitis (sic!) undergoing orthotopic liver transplantation (OLT). Am J Gastroenterol 1998; 93: 481-2.
9. Vergani D, Mieli-Vergani G. Autoimmunity after liver transplantation. Hepatology 2002; 36: 271-6.
10. Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression develop inflammatory bowel disease. Am J Gastroenterol 1997; 92: 279-82.
11. Gurudu SR, Griffel LH, Gialanella RJ, Das KM. Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results. J Clin Gastroenterol 1999; 29: 151-4.
12. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253-61.
13. Ludviksson BR, Ehrhardt RO, Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2 deficient mice. J Immunol 1997; 159: 3622-8.
14. Damoiseaux JG, Van Breda Vriesman PJ. Cyclosporin A-induced autoimmunity: the result of defective de novo T-cell development. Folia Biol (Praha) 1998; 44: 1-9.
15. Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporin A vs tacrolimus) in stable renal allograft recipients. Clin Transplant 1999; 13: 400-9.
16. Mohamed MA, Robertson H, Booth TA, et al. Active TGF-beta1 expression in kidney transplantation: a comparative study of cyclosporin-A (CyA) and tacrolimus (FK506). Transpl Int 2000; 13(Suppl. 1): S295-8.
17. Jiang H, Wynn C, Pan F, Ebbs A, Erickson LM, Kobayashi M. Tacrolimus and cyclosporine differ in their capacity to overcome allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002; 73: 1808-17.
18. Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G. Switch from cyclosporin A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine response. Hum Immunol 2000; 62: 884-97.
19. Wong PY, Portmann B, O'Grady JG, et al. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. J Hepatol 1993; 17: 284-7.
20. Dimitrewski J, Hubscher SG, Mayer AD, Neuberger JM. Recurrence of primary biliary cirrhosis in the liver graft: the effect of immunosuppression. J Hepatol 1996; 24: 253-7.